Results 11 to 20 of about 180,494 (192)

Immunomodulatory therapy in ENT practice

Медицинский совет, 2016
Area Moscow’s regional research clinical institute n.a. M.F. Vladimirskiy Abstract. The article analyzes the experience of application of the immunomodulator Polyoxidonium in patients with respiratory diseases.
D. M. Mustafaev, V. I. Egorov
doaj   +3 more sources

Immunopathogenesis and immunomodulatory therapy for myocarditis. [PDF]

Sci China Life Sci, 2023
Myocarditis is an inflammatory cardiac disease characterized by the destruction of myocardial cells, infiltration of interstitial inflammatory cells, and fibrosis, and is becoming a major public health concern. The aetiology of myocarditis continues to broaden as new pathogens and drugs emerge.
He W, Zhou L, Xu K, Li H, Wang JJ, Chen C, Wang D.   +6 more
europepmc   +3 more sources

Immunomodulatory therapies for COVID-19

Frontiers in Medicine, 2022
PurposeAs COVID-19 disease progresses, the host inflammatory response contributes to hypoxemia and severe and critical illness. In these latter stages of disease, patients may benefit from immunomodulatory therapies to control the aberrant host inflammatory response. In this review, we provide an overview of these therapies and provide summaries of the
Poonam Mathur, Shyamasundaran Kottilil
openaire   +3 more sources

Pharmaco-Immunomodulatory Therapy in COVID-19 [PDF]

Drugs, 2020
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory response. The cytokine storm and viral evasion of cellular immune responses may play an equally important role in the pathogenesis, clinical manifestation, and outcomes of ...
Rizk, John G., Kalantar-Zadeh, Kamyar, Mehra, Mandeep R., Lavie, Carl J., Rizk, Youssef, Forthal, Donald N.   +5 more
openaire   +6 more sources

Immunomodulatory Therapy for MIS-C

Pediatrics, 2023
CONTEXT Studies comparing initial therapy for multisystem inflammatory syndrome in children (MIS-C) provided conflicting results. OBJECTIVE To compare outcomes in MIS-C patients treated with intravenous immunoglobulin (IVIG), glucocorticoids, or the
Ouldali, Naïm, Son, Mary Beth F., Mcardle, Andrew, Vito, Ortensia, Vaugon, Esther, Belot, Alexandre, Leblanc, Claire, Murray, Nancy, Patel, Manish, Levin, Michael, Randolph, Adrienne, Angoulvant, François   +11 more
openaire   +4 more sources

The immunomodulatory effects of antihypertensive therapy: A review

Biomedicine & Pharmacotherapy, 2022
Hypertension remains the leading preventable risk factor for stroke and coronary artery disease, significantly contributing to all-cause global mortality and predisposing patients to renal and heart failure, as well as peripheral vascular disease. Due to the widespread usage of antihypertensive drugs, global mean blood pressure has remained unchanged ...
Dominik, Felkle, Mateusz, Jarczyński, Konrad, Kaleta, Katarzyna, Zięba, Katarzyna, Nazimek   +4 more
openaire   +2 more sources

Efficacy and Safety of Infliximab in HLA-B27-associated Ocular Inflammation Refractory or Intolerant to Conventional Immunomodulatory Therapy

Journal of Ophthalmic & Vision Research, 2020
Purpose: To determine the efficacy and safety of infliximab therapy in patients with HLA B-27-associated ocular inflammation resistant or intolerant to conventional immunomodulatory therapy.
Asima Bajwa, Arash Maleki, Abhishek R Payal, Adriana Fandiño, María Inés Menéndez Padrón, Marisa Walsh, C Stephen Foster   +6 more
doaj   +1 more source

Immunomodulatory Therapy for Ischemic Heart Disease. [PDF]

Circulation
Ischemic heart disease is a leading cause of death worldwide, manifested clinically as myocardial infarction (and ischemic cardiomyopathy. Presently, there exists a notable scarcity of efficient interventions to restore cardiac function after myocardial infarction.
Zhao X, Williamson T, Gong Y, Epstein JA, Fan Y.   +4 more
europepmc   +4 more sources

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination

Frontiers in Medicine, 2023
ObjectivesThis study aimed to assess the duration of humoral responses after two doses of SARS-CoV-2 mRNA vaccines in patients with inflammatory joint diseases and IBD and booster vaccination compared with healthy controls.
Selma Tobudic, Elisabeth Simader, Thomas Deimel, Jennifer Straub, Felix Kartnig, Leonhard X. Heinz, Peter Mandl, Helmuth Haslacher, Thomas Perkmann, Lisa Schneider, Thomas Nothnagl, Helga Radner, Florian Winkler, Florian Winkler, Heinz Burgmann, Karin Stiasny, Gottfried Novacek, Walter Reinisch, Daniel Aletaha, Stefan Winkler, Stephan Blüml   +20 more
doaj   +1 more source

Case report: Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 with severe myocardial dysfunction. Is there any hope in immunotherapy?

Journal of Education, Health and Sport, 2023
Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) develops in a small percentage of children after COVID-19, however, it might cause severe myocardial dysfunction.
Julita Tokarek, Emilian Budny, Renata Szmigielska   +2 more
doaj   +1 more source